FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892561240> ?p ?o ?g. }

• W2892561240 endingPage "96" @default.
• W2892561240 startingPage "1" @default.
• W2892561240 abstract "Background Prostate cancer (PCa) is the most common cancer in men in the UK. Patients with intermediate-risk, clinically localised disease are offered radical treatments such as surgery or radiotherapy, which can result in severe side effects. A number of alternative partial ablation (PA) technologies that may reduce treatment burden are available; however the comparative effectiveness of these techniques has never been evaluated in a randomised controlled trial (RCT). Objectives To assess the feasibility of a RCT of PA using high-intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for intermediate-risk PCa and to test and optimise methods of data capture. Design We carried out a prospective, multicentre, open-label feasibility study to inform the design and conduct of a future RCT, involving a QuinteT Recruitment Intervention (QRI) to understand barriers to participation. Setting Five NHS hospitals in England. Participants Men with unilateral, intermediate-risk, clinically localised PCa. Interventions Radical prostatectomy compared with HIFU. Primary outcome measure The randomisation of 80 men. Secondary outcome measures Findings of the QRI and assessment of data capture methods. Results Eighty-seven patients consented to participate by 31 March 2017 and 82 men were randomised by 4 May 2017 (41 men to the RP arm and 41 to the HIFU arm). The QRI was conducted in two iterative phases: phase I identified a number of barriers to recruitment, including organisational challenges, lack of recruiter equipoise and difficulties communicating with patients about the study, and phase II comprised the development and delivery of tailored strategies to optimise recruitment, including group training, individual feedback and ‘tips’ documents. At the time of data extraction, on 10 October 2017, treatment data were available for 71 patients. Patient characteristics were similar at baseline and the rate of return of all clinical case report forms (CRFs) was 95%; the return rate of the patient-reported outcome measures (PROMs) questionnaire pack was 90.5%. Centres with specific long-standing expertise in offering HIFU as a routine NHS treatment option had lower recruitment rates (Basingstoke and Southampton) – with University College Hospital failing to enrol any participants – than centres offering HIFU in the trial context only. Conclusions Randomisation of men to a RCT comparing PA with radical treatments of the prostate is feasible. The QRI provided insights into the complexities of recruiting to this surgical trial and has highlighted a number of key lessons that are likely to be important if the study progresses to a main trial. A full RCT comparing clinical effectiveness, cost-effectiveness and quality-of-life outcomes between radical treatments and PA is now warranted. Future work Men recruited to the feasibility study will be followed up for 36 months in accordance with the protocol. We will design a full RCT, taking into account the lessons learnt from this study. CRFs will be streamlined, and the length and frequency of PROMs and resource use diaries will be reviewed to reduce the burden on patients and research nurses and to optimise data completeness. Trial registration Current Controlled Trials ISRCTN99760303. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 22, No. 52. See the NIHR Journals Library website for further project information." @default.
• W2892561240 created "2018-10-05" @default.
• W2892561240 creator A5007295795 @default.
• W2892561240 creator A5008243215 @default.
• W2892561240 creator A5010083380 @default.
• W2892561240 creator A5012567235 @default.
• W2892561240 creator A5012694886 @default.
• W2892561240 creator A5015663726 @default.
• W2892561240 creator A5019975245 @default.
• W2892561240 creator A5025426969 @default.
• W2892561240 creator A5025941085 @default.
• W2892561240 creator A5028350848 @default.
• W2892561240 creator A5032231578 @default.
• W2892561240 creator A5035580367 @default.
• W2892561240 creator A5036247334 @default.
• W2892561240 creator A5040752700 @default.
• W2892561240 creator A5047932989 @default.
• W2892561240 creator A5049636639 @default.
• W2892561240 creator A5074827533 @default.
• W2892561240 creator A5077286242 @default.
• W2892561240 creator A5082679849 @default.
• W2892561240 creator A5085691562 @default.
• W2892561240 creator A5086206029 @default.
• W2892561240 creator A5090096123 @default.
• W2892561240 date "2018-09-01" @default.
• W2892561240 modified "2023-10-10" @default.
• W2892561240 title "Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT" @default.
• W2892561240 cites W1495377470 @default.
• W2892561240 cites W1594514919 @default.
• W2892561240 cites W1688227406 @default.
• W2892561240 cites W1774908743 @default.
• W2892561240 cites W1857905445 @default.
• W2892561240 cites W1928246315 @default.
• W2892561240 cites W1947552921 @default.
• W2892561240 cites W1966280304 @default.
• W2892561240 cites W1974182592 @default.
• W2892561240 cites W1976133111 @default.
• W2892561240 cites W1982386852 @default.
• W2892561240 cites W1983145936 @default.
• W2892561240 cites W1990119121 @default.
• W2892561240 cites W1990166011 @default.
• W2892561240 cites W1996809772 @default.
• W2892561240 cites W2001143432 @default.
• W2892561240 cites W2001769285 @default.
• W2892561240 cites W2002204921 @default.
• W2892561240 cites W2002331028 @default.
• W2892561240 cites W2004909463 @default.
• W2892561240 cites W2009414295 @default.
• W2892561240 cites W2029578938 @default.
• W2892561240 cites W2031535915 @default.
• W2892561240 cites W2037331044 @default.
• W2892561240 cites W2045644088 @default.
• W2892561240 cites W2051980021 @default.
• W2892561240 cites W2058971336 @default.
• W2892561240 cites W2060631572 @default.
• W2892561240 cites W2083043726 @default.
• W2892561240 cites W2083476097 @default.
• W2892561240 cites W2086240335 @default.
• W2892561240 cites W2087810839 @default.
• W2892561240 cites W2089625668 @default.
• W2892561240 cites W2089948140 @default.
• W2892561240 cites W2095748322 @default.
• W2892561240 cites W2096500246 @default.
• W2892561240 cites W2110032527 @default.
• W2892561240 cites W2112143708 @default.
• W2892561240 cites W2123572561 @default.
• W2892561240 cites W2128614409 @default.
• W2892561240 cites W2129530569 @default.
• W2892561240 cites W2129915352 @default.
• W2892561240 cites W2133124363 @default.
• W2892561240 cites W2134168106 @default.
• W2892561240 cites W2134766389 @default.
• W2892561240 cites W2135369558 @default.
• W2892561240 cites W2137282952 @default.
• W2892561240 cites W2143059818 @default.
• W2892561240 cites W2143962930 @default.
• W2892561240 cites W2144498681 @default.
• W2892561240 cites W2151417425 @default.
• W2892561240 cites W2153361568 @default.
• W2892561240 cites W2153386196 @default.
• W2892561240 cites W2165544861 @default.
• W2892561240 cites W2166164748 @default.
• W2892561240 cites W2166423862 @default.
• W2892561240 cites W2172038823 @default.
• W2892561240 cites W2225234007 @default.
• W2892561240 cites W2276340295 @default.
• W2892561240 cites W2283544820 @default.
• W2892561240 cites W2313666013 @default.
• W2892561240 cites W2340422569 @default.
• W2892561240 cites W2345839861 @default.
• W2892561240 cites W2414442728 @default.
• W2892561240 cites W2493763979 @default.
• W2892561240 cites W2502134830 @default.
• W2892561240 cites W2510720854 @default.
• W2892561240 cites W2519027667 @default.
• W2892561240 cites W2539317882 @default.
• W2892561240 cites W2572357835 @default.
• W2892561240 cites W2577453388 @default.

• next